ization of anti-infective
drug products that fulfill substantial unmet medical needs in the treatment
of infectious disease. The Company is developing anti-infective drugs based
on its novel biological finding that bacteria exposed to antibiotics in
front- loaded staccato bursts, or "pulses," are killed more efficiently and
effectively than those under standard treatment regimens. Based on this
finding, MiddleBrook has developed a proprietary, once-a-day pulsatile
delivery technology called PULSYS(TM). The Company currently markets the
Keflex(R) brand of cephalexin and has received regulatory approval for
MOXATAG(TM) -- the first and only once-daily amoxicillin product approved
for marketing in the U.S. For more on MiddleBrook, please visit
http://www.middlebrookpharma.com.

This announcement contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. These
statements are based on MiddleBrook's current expectations and assumptions.
These statements are not guarantees of future performance and are subject
to a number of risks and uncertainties that would cause actual results to
differ materially from those anticipated. The words, "believe," "expect,"
"intend," "anticipate," and variations of such words, and similar
expressions identify forward-looking statements, but their absence does not
mean that the statement is not forward- looking. Statements in this
announcement that are forward-looking include, but are not limited to,
statements about the Company's future development plans, clinical trials,
potential commercial success, and any financial forecasts included in this
announcement.

The actual results realized by MiddleBrook could differ materially from
these forward-looking statements, depending in particular upon the risks
and uncertainties described in the Company's fil'/>"/>

(Date:3/3/2015)... 03, 2015 Crown Bioscience, Inc., a ... launched a new Life Science division specializing in in ... , The first products released include in vivo ... soon to be released in vivo grade monoclonal antibodies ... expand their life science portfolio with additional antibody products ...

(Date:3/3/2015)... New Jersey (PRWEB) March 03, 2015 ... has announced today that it has acquired The ... Terms of the transaction were not announced. , ... services to the energy sector including oil and ... energy, and fossil and nuclear power sectors. The ...

(Date:3/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/gxqhg9/gene_therapy ... new report "Gene Therapy - Technologies, Markets ... Gene therapy technologies are described in ... therapy with genetically modified vectors. Gene therapy is ... routes of administration as well as targeted gene ...

... Bay, Wis. - Whenever the title executive vice president ... an established part of management. So it is with Judy ... National following a career that she thought was winding ... Green Bay-based provider of global transportation, logistics, and intermodal services, ...

... students are no longer interested in technology careers? , ... Area Technical College has won first place in ... beating four teams from Minnesota, and later advanced to ... third place. , ,The competitions were open to students ...

... a series of articles on raising capital from investors. This installment ... the time when raising equity capital, the offering terms are summarized ... When dealing with angel investors , it is typical ... prospective angel investors will want to negotiate the initial term sheet, ...

(Date:2/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/sxwl43/global_2d_gesture ... "Global 2D Gesture Recognition Market 2015-2019" report ... forecast the Global 2D Gesture Recognition market to ... period 2014-2019 The increased demand for ... of the major trends in the market. The ...

... interested in natural history but it also challenges those people ... life on Earth. Thats the view of Dr Robert Lambert, ... of Nottingham, who has just returned from the Antarctic in ... Antarctica Tour Operators (IAATO). Dr Lambert, who is a ...

... University of Missouri scientist Ray Semlitsch studies creatures most ... at night and thrive in the shallow, cool, wet ... A collaborative study, with MU graduate student Bill Peterman, ... biomass (total mass of an organism in an area) ...